Themes — uterine adenosarcoma patient-voice layer¶

Last curated: 2026-09-01. Each theme is supported by ≥2 independent sources. A PubMed search rerun on 2026-09-01 found no adenosarcoma-specific qualitative cohort; themes are labelled uterine-sarcoma class or adenosarcoma-clinical (the latter when the second source is a clinical series documenting the same phenomenon from the medical side).

T1. Diagnosed as a fibroid or polyp¶

The presenting illness is bleeding and a mass that is treated as benign until it is not. den Hollander’s mixed-methods paper is titled with a patient sentence: “I thought I had fibroids, and now I don’t” (den Hollander 2022, PMID 35443673). Clement documented five patients who presented repeatedly with “recurrent polyps” later recognised as adenosarcoma (Clement 1990, PMID 2156771). Tate reported that preoperative radiology and pathology sometimes failed to reach the correct diagnosis (Tate 2018, PMID 29441675). Occult uterine sarcoma among presumed-leiomyoma hysterectomies is quantified at 1 in 278 (Raine-Bennett 2016, PMID 26646120).

Sources: PMID 35443673, 2156771, 29441675, 26646120.

T2. Shock of diagnosis and missing sarcoma knowledge¶

den Hollander: shock of diagnosis and “dealing with lacking knowledge regarding sarcoma” affected HRQoL for patients and professionals; these items were absent from EORTC QLQ-C30 and QLQ-EN24 (den Hollander 2022, PMID 35443673). NCI and ACS maintain general patient information for uterine sarcoma; the old ACS “questions to ask” URL redirected to its detection/diagnosis/staging hub when re-fetched, so no question-list claim is retained. ESGO and French GSF locate care in specialist networks (Ray-Coquard 2024, PMID 39322612; Karabajakian 2023, PMID 37202293).

Sources: PMID 35443673, 39322612, 37202293; NCI and ACS pages re-fetched 2026-09-01.

T3. Sexual, urological, and menopausal aftermath of standard surgery¶

den Hollander: the most commonly reported physical issues were sexual dysfunction and urological symptoms; hormone-related issues and missing menopausal items on EORTC instruments were explicit findings (den Hollander 2022, PMID 35443673). Standard treatment is hysterectomy usually with BSO (Nathenson 2016, PMID 27718181; Friedlander 2014, PMID 25341585), which produces surgical menopause in premenopausal patients. Ovarian preservation is practised in small subsets without histology-specific proof (Li 2022, PMID 35005157; Nasioudis 2017, PMID 28541635).

Sources: PMID 35443673, 27718181, 25341585, 35005157.

T4. Fertility is ended by the standard operation and not replaced by a pathway¶

Clement’s age range starts at 14; Yuan’s median is 47.5 with a large cervical-primary share (Clement 1990, PMID 2156771; Yuan 2019, PMID 31139558). Fertility-sparing management is a 20-year single-patient follow-up plus a 7-patient stage IA subset (L’Heveder 2019, PMID 31584132; Yuan 2019, PMID 31139558). Piątek’s mixed series of 11 (3 adenosarcomas) observed a low chance of childbearing in adenosarcoma (Piątek 2022, PMID 36012998). Guidelines do not establish fertility-sparing as standard (Karabajakian 2023, PMID 37202293).

Sources: PMID 2156771, 31139558, 31584132, 36012998, 37202293.

T5. Fear of recurrence is rational, and follow-up is untested¶

den Hollander: fear of recurrence (and of death, and of sex) was a mental-health theme (den Hollander 2022, PMID 35443673). Clement: 23/100 recurred, a third of recurrences at ≥5 years (Clement 1990, PMID 2156771). Carroll stage I: 77% vs 22% by sarcomatous overgrowth (Carroll 2014, PMID 25449308). No prospective surveillance schedule has been tested (recurrence-and-surveillance).

Sources: PMID 35443673, 2156771, 25449308.

T6. Isolation inside a rare-cancer system; no dedicated trial, no dedicated organisation¶

Searches rerun 2026-09-01 found no adenosarcoma-only organisation (organizations.md). No adenosarcoma-only randomised trial or reported adenosarcoma-specific randomised outcome was identified (clinical-trials-landscape); an older mixed-histology phase 3 record explicitly included adenosarcoma but has unknown status and no posted results (NCT00162721). FUCHSia enrolled 17 patients across several low-grade gynaecologic cancers (NCT03926936). Sarcoma UK and SFA are sarcoma-class homes; FWC is a gynaecologic-cancer home. den Hollander’s “lacking knowledge regarding sarcoma” is the same isolation from the inside (PMID 35443673).

Sources: PMID 35443673; NCT00162721; NCT03926936; organisation homepages re-fetched 2026-09-01, except SFA (HTTP 403; changing claims removed).

Themes not promoted¶

Single-source observations were not promoted: the short patient perspective in one fertility-sparing case report (Ziegler 2026, PMID 42334466); individual named patient stories on SFA’s hub (ethics: not catalogued); closed-forum content (not accessed). No adenosarcoma-specific sexual-function score was identified in the 2026-09-01 PubMed search.